Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells

Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma

(2017) Ildikó Krencz et al.   HUMAN PATHOLOGY

IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced

(2017) Huixia Zhu et al.   PLoS One

mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells

(2016) Raju V. Pusapati et al.   CANCER CELL

Characterisation of bioenergetic pathways and related regulators by multiple assays in human tumour cells

(2016) A. Jeney et al.   Cancer Cell International

mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress

(2016) J. Li et al.   CANCER RESEARCH

Serine Metabolism Links Tumor Suppression to the Epigenetic Landscape

(2016) Xia Gao et al.   Cell Metabolism

Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer

(2016) O. Clark et al.   CLINICAL CANCER RESEARCH

Emerging targeted therapies for glioma

(2016) Julie J Miller et al.   EXPERT OPINION ON EMERGING DRUGS

mTOR activity and its prognostic significance in human colorectal carcinoma depending on C1 and C2 complex-related protein expression

(2016) Tamás Sticz et al.   JOURNAL OF CLINICAL PATHOLOGY

mTORC1 alters the expression of glycolytic genes by regulating KPNA2 abundances

(2016) Xianwei Chen et al.   Journal of Proteomics

The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells

(2016) Annette Brenner et al.   MOLECULES

Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition

(2016) Marco Sciacovelli et al.   NATURE

LKB1 loss links serine metabolism to DNA methylation and tumorigenesis

(2016) Filippos Kottakis et al.   NATURE

A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors

(2016) Oren J. Becher et al.   PEDIATRIC BLOOD & CANCER

Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation

(2016) Noémi Nagy et al.   TUMOR BIOLOGY

The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway

(2016) Mélissa Carbonneau et al.   Nature Communications

The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study

(2016) Peter Tan et al.   Oncotarget

RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR

(2016) Nneha Sakre et al.   Oncotarget

Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling

(2016) Elizabeth Allen et al.   Cell Reports

The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells

(2016) Jing-Yi Chen et al.   Scientific Reports

Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer

(2016) Hugh Colvin et al.   Scientific Reports

Glutaminolysis and autophagy in cancer

(2015) Victor H Villar et al.   Autophagy

Elevated Rictor expression is associated with tumor progression and poor prognosis in patients with gastric cancer

(2015) Yuhai Bian et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling

(2015) Xudong Fu et al.   Cell Metabolism

Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway

(2015) Valéry L. Payen et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

mTOR signaling in cellular and organismal energetics

(2015) Verena Albert et al.   CURRENT OPINION IN CELL BIOLOGY

Oncometabolites: tailoring our genes

(2015) Stefan Nowicki et al.   FEBS Journal

Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma

(2015) Hideki Makinoshima et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment

(2015) Kazuhiro Tanaka et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolic reprogramming: the emerging concept and associated therapeutic strategies

(2015) Go J. Yoshida   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H+ symporters

(2015) Ibtissam Marchiq et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

NADP+-IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance

(2015) Feng Li et al.   MOLECULAR CELL

Isocitrate dehydrogenase mutations in gliomas

(2015) Matthew S. Waitkus et al.   NEURO-ONCOLOGY

Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells

(2015) Luyuan Li et al.   PLoS One

Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes

(2015) Yonghui Jin et al.   PLoS One

Lactate does not activate NF-κB in oxidative tumor cells

(2015) Vincent F. Van Hée et al.   Frontiers in Pharmacology

Determination of energy metabolites in cancer cells by porous graphitic carbon liquid chromatography electrospray ionization mass spectrometry for the assessment of energy metabolism

(2014) Norbert Szoboszlai et al.   ANALYTICA CHIMICA ACTA

IDH1 R132H Mutation Generates a Distinct Phospholipid Metabolite Profile in Glioma

(2014) Morteza Esmaeili et al.   CANCER RESEARCH

Rapamycin: One Drug, Many Effects

(2014) Jing Li et al.   Cell Metabolism

Oncometabolites-driven tumorigenesis: From genetics to targeted therapy

(2014) Aurélie Morin et al.   INTERNATIONAL JOURNAL OF CANCER

Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

(2014) R. Dienstmann et al.   MOLECULAR CANCER THERAPEUTICS

Making new contacts: the mTOR network in metabolism and signalling crosstalk

(2014) Mitsugu Shimobayashi et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

A High-Throughput Fluorimetric Assay for 2-Hydroxyglutarate Identifies Zaprinast as a Glutaminase Inhibitor

(2014) A. Elhammali et al.   Cancer Discovery

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Alterations of metabolic genes and metabolites in cancer

(2012) Eric K. Oermann et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

mTOR upregulation of glycolytic enzymes promotes tumor development

(2011) Xiaojun Zha et al.   CELL CYCLE

LC–MS analysis of low molecular weight organic acids derived from root exudation

(2010) Leonhard Jaitz et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1

(2010) Katrin Düvel et al.   MOLECULAR CELL

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY